How Much Weight Can You Lose on Zepbound? Trial Averages
Zepbound has the clearest answer of any GLP-1 brand to the how much question, because its approval rests on a trial designed to measure weight loss itself. This page gives the SURMOUNT-1 averages, translates them into real weights with simple arithmetic, and explains the dose and variation behind them. It is education only, not medical advice.
The short answer from SURMOUNT-1
In SURMOUNT-1, the main trial behind the Zepbound weight management approval, adults taking tirzepatide at the 15 mg dose lost an average of 20.9 percent of their body weight at 72 weeks. Participants also received support with eating and activity throughout the trial. The 15 mg dose is the highest maintenance dose on the Zepbound label, and the trial ran for well over a year, so the figure describes the full program at full dose over full time. It is the strongest average result in the GLP-1 class trials, and also the one most often quoted without its conditions attached.
Zepbound is the weight management label of tirzepatide, the same drug sold as Mounjaro for type 2 diabetes. It is approved for chronic weight management in adults with obesity or overweight, and additionally for moderate to severe obstructive sleep apnea in adults with obesity. The dosing schedule starts at 2.5 mg once weekly and rises by 2.5 mg steps, at least four weeks apart, toward maintenance doses of 5 mg, 10 mg or 15 mg once weekly.
What 20.9 percent means at real starting weights
Percentages are hard to picture, so here is the trial average translated with simple arithmetic. These are worked examples of the same 20.9 percent applied to round starting weights, not predictions for any individual. A person starting at 100 kilograms who matched the average exactly would lose about 21 kilograms. A person starting at 120 kilograms would lose about 25 kilograms at the same percentage. A person starting at 80 kilograms would lose about 17 kilograms. The pattern to notice is that a percentage average automatically scales with starting weight, which is one reason heavier participants in trials often report larger absolute losses.
The same arithmetic runs in the other direction and is worth doing for your own expectations. Pick your starting weight, apply a percentage, and you have a rough sense of scale. The GLP-1 weight loss calculator on this site does exactly this calculation. What no calculator can tell you is where you personally will land relative to the average, because that depends on dose, time, tolerability and habits, which the next sections cover.
Dose matters, described in words
SURMOUNT-1 studied more than one dose, and the pattern was clear and dose related. The 15 mg group averaged the largest loss, the figure quoted above. Groups assigned to lower maintenance doses averaged less, with the losses stepping down as the dose stepped down. This page deliberately reports only the verified 15 mg figure as a number, because it is the result this site can stand behind precisely, but the direction of the finding is not in doubt: within the studied range, more dose meant more average weight loss, balanced against more side effects for some people.
That trade off is why the label offers three maintenance doses rather than one. A prescriber may keep a patient at 5 mg or 10 mg because that dose is working well enough, or because higher doses are not tolerated comfortably. A lower maintenance dose is not a failed treatment. It simply comes with a lower expected average, and for many people the difference in comfort is worth more than the difference in the average.
An average hides a wide range
Within the SURMOUNT-1 average, individual outcomes spread widely, as they do in every weight trial. Some participants lost far more than 20.9 percent, some landed near the average, and some lost modest amounts despite a year and a half of treatment. Trial averages describe the center of a group. They cannot sort people in advance, and researchers cannot yet reliably predict who will be a strong responder before treatment starts.
Several influences show up again and again. Reaching and staying on a dose matters, because interruptions and long holds dilute the effect. Eating patterns matter: the medicine suppresses appetite powerfully, but protein intake protects muscle, and very low total intake can leave people undernourished rather than well. Activity, sleep, other medicines and conditions such as thyroid disease all add their own push or drag. The fair way to use the trial figure is as a realistic center of expectation for full dose treatment over a similar period, not as a personal target to hit or miss.
The timeline behind the average
The 72 week time frame is part of the result, not a footnote. Zepbound doses rise by 2.5 mg at a time with at least four weeks at each step, so even an uninterrupted climb to 15 mg takes around five months, and real climbs include pauses. Most of the trial period was therefore spent at maintenance, with weight coming off gradually throughout. Spread evenly as simple arithmetic, 20.9 percent over the roughly 16 and a half months of the trial is a rough average of about 1.3 percent of starting weight per month. Real progress is not even: it is slower during titration, and plateaus interrupt it at every stage.
Knowing this protects against the two most common disappointments. The first is expecting trial scale change in the first two or three months, when the dose is still low. The second is treating a plateau at month eight as the end of the story, when the trial averages kept improving well past that point. Monthly weighing, or weekly weighing averaged over the month, shows the trend far more honestly than daily numbers, which mostly track water and digestion.
Keeping the result, and the cautions
Tirzepatide stopping data underlines why Zepbound is framed as long term treatment. In SURMOUNT-4, participants who had lost weight on tirzepatide and were then switched to placebo regained about half of the lost weight over the following year, while those who continued treatment kept losing a little more. If you stop, some regain should be expected and planned for, ideally with your prescriber, rather than discovered with dismay.
For safety, Zepbound carries the class boxed warning about thyroid C cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Common effects are gastrointestinal, especially around dose increases. The eating pages on this site cover protein, fiber and fluids, which support both comfort and the quality of the weight lost. Decisions about starting, dosing and stopping belong with your own doctor or pharmacist.
Frequently asked questions
How much weight can you lose on Zepbound?
In SURMOUNT-1, adults on the 15 mg maintenance dose lost an average of 20.9 percent of their body weight at 72 weeks, with diet and activity support. Lower maintenance doses averaged less. It is a group average at full dose over more than a year, and individual results spread widely around it.
How much is 20.9 percent in real weight?
It scales with your starting weight. As simple arithmetic, 20.9 percent of 100 kilograms is about 21 kilograms, of 120 kilograms is about 25 kilograms, and of 80 kilograms is about 17 kilograms. These are translations of the trial average, not predictions of what you personally will lose.
Does the Zepbound dose change how much you lose?
Yes, in the trial the average loss rose with the dose, and the 15 mg group averaged the most. The label maintenance doses are 5 mg, 10 mg or 15 mg once weekly, and prescribers balance expected effect against tolerability. Staying on a lower dose that suits you is a normal outcome, not a failure.
How fast does Zepbound weight loss happen?
Gradually, over the length of the trial and beyond titration. Doses rise in 2.5 mg steps at least four weeks apart, so reaching maintenance takes months. Spread evenly, the trial total is a rough average of about 1.3 percent of starting weight per month, but real progress comes in uneven stretches with plateaus.
What happens to the weight if I stop Zepbound?
Regain is the usual pattern. In SURMOUNT-4, people switched to placebo after losing weight on tirzepatide regained about half of the lost weight within a year, while those who continued maintained and slightly extended their loss. Long term planning with your prescriber is the standard approach.